A point-of-care solution, regardless of the situation.

Because ClotChip® technology is a global assay, it is uniquely capable of serving urgent needs for a number of clinical markets. ClotChip® is ideal for assessment of whole-blood coagulation for congenital disorders, monitoring treatment with anticoagulants, trauma applications in civilian and military sectors, and as a pre-surgical screening tool of assessment.

Congenital Disorders

Congenital hemophilia affects ~25,00 people in the U.S. and ~400,000 people globally according to the Centers for Disease Control and Prevention (CDC).

With hemophilia, every bleed is life-threatening yet there is currently no viable point-of-care diagnostic test to inform clinician care.

ClotChip® is poised to be the point-of-care diagnostic device to inform clinicians in treating those affected by hemophilia.

Oral Anticoagulant Therapy Monitoring

Therapeutic use of anticoagulants is common in prevention and treatment of potentially deadly blood clots and the use of Direct Oral Anticoagulants (DOACs) has gained favor in replacing use of traditional blood thinners such as heparins and vitamin K antagonists (Warfarin).

DOAC therapeutics work by blocking either thrombin directly, or factor Xa within the coagulation cascade. While these drugs are beneficial overall, there are numerous reports of life threatening spontaneous bleeding in patients undergoing treatment with these therapeutics.

ClotChip® is positioned to be the point-of-care diagnostic device to inform clinicians in monitoring and informing treatment with DOAC therapies. Specifically, XaTek® is pursuing the use case for ClotChip® as a peri-operative screening tool for patients on DOAC therapy immediately prior to an invasive procedure.

See press release on FDA’s Breakthrough Device Designation.


Uncontrolled bleeding from traumatic injuries in civilian and military settings often leads to organ failure and, eventually, death. Currently there is no accessible method for field or trauma center assessment of a patient’s coagulation state.

ClotChip® is ready to be the point-of-care diagnostic device used in trauma centers, and could be adapted for field use in ambulances and/or helicopters, to inform care and use of precious blood products.

The ruggedization of ClotChip® for field use is currently being funded by the Department of Defense’s Combat Readiness Medical Research Program, in cooperation with the U.S. Navy.

See press release on XaTek’s cooperative work with the U.S. Navy.

Pre-surgical screening

Coming soon

Technology questions?